Rudiments of subgroup analyses

Progress in Cardiovascular Diseases

Volumn 54, Issue 4, 2012, Pages 338-342

  Moyé, Lemuel A ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; Secondary evaluation; Subgroup analyses

Indexed keywords

AMLODIPINE;

ANALYTICAL ERROR; ARTICLE; CLINICAL RESEARCH; DATA ANALYSIS; HEART FAILURE; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE;

CARDIOVASCULAR DISEASES; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84855409136     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.07.005     Document Type: Article

References (39)

1. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the Survival and Ventricular Enlargement Trial. N Eng J Med 1992, 327:669-677.
2. Sacks F.M., Pfeffer M.A., Moyé L.A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
3. Prevention of stroke by antihypertensive drug therapy in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. The SHEP Cooperative Research Group.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
5. Moyé L.A., Pfeffer M.A., Wun C.C., et al. Uniformity of captopril benefit in the post infarction population: subgroup analysis in SAVE. Eur Heart J 1994, 15(Suppl B):2-8.
6. Lewis S.J., Moyé L.A., Sacks F.M., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998, 129:681-689.
7. Lewis S.J., Sacks F.M., Mitchell J.S., et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998, 32:140-146.
8. Hernández A.V., Boersma E., Murray G.D., et al. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?. Am Heart J 2006, 151:257-264.
9. Exner D.V., Dreis D.L., Domanski M.J., et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. N Engl J Med 2001, 334:1351-1357.
10. Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001, 334:1358-1365. for the U.S. Carvedilol Heart Failure Study Group.
11. Stolberg S.G. Should a pill be colorblind?. N. Y. Times 2001, 1. [Week Rev May 13].
12. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodopine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107-1114. for the Prospective Randomized Amlodipine Survial Evaluation Study Group.
13. Packer M. 2000.
14. Peto R., Collins R., Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995, 48:23-40.
15. MRFIT Investigators Multiple risk factor intervention trial. JAMA 1982, 248:1465-1477.
16. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction-ISIS-1. Lancet 1986, ii:57-66. ISIS-I Collaborative Group.
17. Lee K.L., McNeer F., Starmer C.F., et al. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation 1980, 61:508-515.
18. Assmann S., Pocock S., Enos L., et al. Subgroup analysis and other misuses of baseline data in clinical trials. Lancet 2000, 355:1064-1069.
19. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 1982, 14:473-482.
20. Pocock S.J. Clinical trials: a practical approach 1983, 213-215. John Wiley & Sons, Chichester, UK.
21. Friedman L., Furberg C., DeMets D.L. Fundamentals of clinical trials 1996, Springer, New York, NY. 3rd ed.
22. Meinert C.L. Clinical trials design, conduct, and analysis 1986, Oxford University Press, New York, NY.
23. Moyé L.A. Random research. Circulation. 2001, 103:3150-3153.
24. Yusef S., Wittes J., Probstfield J., et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991, 266:93-98.
25. Peduzzi P., Wittes J., Deter K., et al. Analysis as-randomized and the problem of non-adherence; an example from the veterans affairs randomized trial of coronary artery bypass surgery. Statist Med 1993, 12:1185-1195.
26. Moyé L.A., Deswal A. Trials with trials: confirmatory subgroup analyses in controlled clinical experiments. Control Clin Trials 2001, 22:605-619.
27. Miles J.L. Data torturing. N Engl J Med 1993, 329:1196-1199.
28. Bonferroni C.E. Il calcolodelleassicurazionisugruppi di teste. Studi in onore del Professore Salvatore OrtuCarboni 1935, 13-60. [Rome.].
29. Dunn O.J. Confidence intervals for the means of dependent, normally distributed variables. J Am Stat Assoc 1959, 54:613-621.
30. Dunn O.J. Multiple comparisons among means. J Am Stat Assoc 1961, 56:52-54.
31. Westfall P.H., Young S.S., Wright S.P. Adjusting P-values for multiplicity. Biometrics 1993, 49:941-945.
32. Westfall P.H., Young S. "P value adjustments for multiple tests in multivariate binomial models". J Am Stat Assoc 1989, 84:780-786.
33. Westfall P.H., Krishnen A., Young S.S. Using prior information to allocate significance levels for multiple endpoints. Statist Med 1998, 17:2107-2119.
34. Moyé L.A., Baraniuk S. Dependence, hyperdependence, and hypothesis testing in Clinical Trials. Contemp Clin Trials 2007, 1:68-78.
35. Moyé L. Statistical reasoning in medicine: the intuitive P value primer 2000, Springer-Verlag, New York, NY.
36. Moyé L.A. Multiple analyses in clinical trials: fundamentals for investigators 2003, Springer, New York, NY.
37. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.
38. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005, 365:1308.
39. Wactawski-Wende J., Kotchen J.M., Anderson G.L., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.